Concr

Concr

Techbio company that uses established methods from astrophysics to accurately predict patient outcomes and treatment response to novel and existing cancer therapies.

  • Edit
Get premium to view all results
DateInvestorsAmountRound
-investor investor investor investor

€0.0

round
investor

€0.0

round
investor

€0.0

round
investor

€0.0

round
investor

€0.0

round
investor investor investor investor

€0.0

round
N/A

€0.0

round
*

N/A

Grant
Total Funding000k
Notes (0)
More about Concr
Made with AI
Edit

ConcR is a pioneering company in the field of oncology, leveraging advanced software to identify complex predictive biomarkers from multi-omic data. This technology is instrumental in guiding clinical trial cohort selection, optimizing combination therapy strategies, and enhancing the market access potential of novel therapeutic candidates. By applying their solutions in the pre-clinical and clinical translation phases, ConcR aims to shorten R&D timelines and predict the sensitivity of cell lines to new drugs. The company serves both clinicians and pharmaceutical companies, providing decision support tools specifically for the treatment of pancreatic ductal adenocarcinoma and triple-negative breast cancer. ConcR's holistic approach, which integrates multiple data sources and methodologies, sets it apart in terms of accuracy and specificity. The company's mission is to reduce the uncertainty in treating cancer and developing new cancer therapeutics, with plans to expand into other indications such as colorectal, prostate, and ovarian cancers.

Keywords: oncology, biomarkers, clinical trials, cancer therapy, multi-omic data, R&D, decision support, pancreatic cancer, breast cancer, pharmaceutical.

Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.
Book a Demo